Increased MALAT1 Expression Predicts Poor Prognosis in Primary Gastrointestinal Diffuse Large B-cell Lymphoma

Overview

Journal Clin Exp Med

Specialty General Medicine

Date 2021 Aug 24

PMID 34427833

Citations 4

Authors

Zhengzi Qian

Leiyuan Chen

Xinyuan Wang

Yutian Kan

Yafei Wang

Yong Yu

Xiaofang Wang

Zhigang Zhao

Hongliang Yang

Peng Ge

Tingting Ding

Qiongli Zhai

Haifeng Zhao

Affiliations

Soon will be listed here.

Abstract

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is involved in the pathogenesis and progression of several cancers. However, the potential effect of MALAT1 in primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) has not been elucidated. This study aimed to explore the prognostic value of MALAT1 in patients with PGI-DLBCL. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to determine the expression of MALAT1 in 90 patients with PGI-DLBCL. MALAT1 was remarkably upregulated in PGI-DLBCL tissues compared to paired adjacent non-tumor tissues (P < 0.001), and the area under the receiver operating characteristic (ROC) curve (AUC) was 0.838. MALAT1 expression was further increased in the non-germinal center B-cell-like (non-GCB), advanced stage (stages IIE-IV) and International Prognostic Index (IPI) score (3-5) groups (P = 0.01, P < 0.001 and P < 0.001, respectively). Furthermore, Kaplan-Meier analysis showed that elevated MALAT1 expression correlated with inferior overall survival (OS) and progression-free survival in PGI-DLBCL patients (P < 0.001 and P < 0.001, respectively), and our multivariate analysis results suggested that upregulation of MALAT1 and high IPI score (3-5) were two unfavorable prognostic factors for PGI-DLBCL. In conclusion, our results demonstrate that MALAT1 may serve as a novel prognostic biomarker and an ideal therapeutic target for patients with PGI-DLBCL.

Citing Articles

Evaluation of the clinical significance of long non-coding RNA genetic variants in human lung adenocarcinoma.

Lin S, Lu J, Hsieh W, Chou Y, Su T, Tsai T Aging (Albany NY). 2024; 16(6):5740-5750.

PMID: 38517388 PMC: 11006483. DOI: 10.18632/aging.205675.

Long non-coding RNA as a potential diagnostic biomarker in head and neck squamous cell carcinoma: A systematic review and meta-analysis.

Masrour M, Khanmohammadi S, Fallahtafti P, Rezaei N PLoS One. 2023; 18(9):e0291921.

PMID: 37733767 PMC: 10513217. DOI: 10.1371/journal.pone.0291921.

LncRNA MALAT1 signaling pathway and clinical applications in overcome on cancers metastasis.

Mazarei M, Rabori V, Ghasemi N, Salehi M, Rayatpisheh N, Jahangiri N Clin Exp Med. 2023; 23(8):4457-4472.

PMID: 37695391 DOI: 10.1007/s10238-023-01179-x.

Long non-coding RNA as a novel biomarker and therapeutic target in aggressive B-cell non-Hodgkin lymphoma: A systematic review.

Khanmohammadi S, Fallahtafti P J Cell Mol Med. 2023; 27(14):1928-1946.

PMID: 37246627 PMC: 10339099. DOI: 10.1111/jcmm.17795.

References

Nakamura S, Matsumoto T . Gastrointestinal lymphoma: recent advances in diagnosis and treatment. Digestion. 2013; 87(3):182-8. DOI: 10.1159/000350051. View

Wang T, Gui W, Shen Q . Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis. Med Oncol. 2009; 27(3):661-6. DOI: 10.1007/s12032-009-9265-1. View

Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N . Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma. 2006; 47(10):2140-6. DOI: 10.1080/10428190600709226. View

Koch P, del Valle F, Berdel W, Willich N, Reers B, Hiddemann W . Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001; 19(18):3861-73. DOI: 10.1200/JCO.2001.19.18.3861. View

Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M . Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer. 2003; 97(10):2462-73. DOI: 10.1002/cncr.11415. View

Nagakita K, Takata K, Taniguchi K, Miyata-Takata T, Sato Y, Tari A . Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P. Pathol Int. 2016; 66(8):444-52. DOI: 10.1111/pin.12439. View

Liu Y, Yu K, Li M, Zeng K, Wei J, Li X . EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features. Hum Pathol. 2017; 64:213-221. DOI: 10.1016/j.humpath.2017.04.011. View

Juarez-Salcedo L, Sokol L, Chavez J, Dalia S . Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment. Cancer Control. 2018; 25(1):1073274818778256. PMC: 6028178. DOI: 10.1177/1073274818778256. View

Schmitt A, Chang H . Long Noncoding RNAs in Cancer Pathways. Cancer Cell. 2016; 29(4):452-463. PMC: 4831138. DOI: 10.1016/j.ccell.2016.03.010. View

10.

Bartonicek N, Maag J, Dinger M . Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer. 2016; 15(1):43. PMC: 4884374. DOI: 10.1186/s12943-016-0530-6. View

11.

Bhan A, Soleimani M, Mandal S . Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res. 2017; 77(15):3965-3981. PMC: 8330958. DOI: 10.1158/0008-5472.CAN-16-2634. View

12.

Ponting C, Oliver P, Reik W . Evolution and functions of long noncoding RNAs. Cell. 2009; 136(4):629-41. DOI: 10.1016/j.cell.2009.02.006. View

13.

Iyer M, Niknafs Y, Malik R, Singhal U, Sahu A, Hosono Y . The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015; 47(3):199-208. PMC: 4417758. DOI: 10.1038/ng.3192. View

14.

Shen J, Siegel A, Remotti H, Wang Q, Shen Y, Santella R . Exploration of Deregulated Long Non-Coding RNAs in Association with Hepatocarcinogenesis and Survival. Cancers (Basel). 2015; 7(3):1847-62. PMC: 4586798. DOI: 10.3390/cancers7030865. View

15.

Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M . A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011; 147(2):358-69. PMC: 3234495. DOI: 10.1016/j.cell.2011.09.028. View

16.

Martianov I, Ramadass A, Serra Barros A, Chow N, Akoulitchev A . Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. Nature. 2007; 445(7128):666-70. DOI: 10.1038/nature05519. View

17.

Sleutels F, Zwart R, Barlow D . The non-coding Air RNA is required for silencing autosomal imprinted genes. Nature. 2002; 415(6873):810-3. DOI: 10.1038/415810a. View

18.

Tian D, Sun S, Lee J . The long noncoding RNA, Jpx, is a molecular switch for X chromosome inactivation. Cell. 2010; 143(3):390-403. PMC: 2994261. DOI: 10.1016/j.cell.2010.09.049. View

19.

Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider P . MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003; 22(39):8031-41. DOI: 10.1038/sj.onc.1206928. View

20.

Amodio N, Raimondi L, Juli G, Stamato M, Caracciolo D, Tagliaferri P . MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol. 2018; 11(1):63. PMC: 5941496. DOI: 10.1186/s13045-018-0606-4. View